Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin and Etoposide With or Without Paclitaxel in Extensive Small Cell Lung Cancer
NCT00003299Phase 3Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Apr 1998
- Primary completion
- Jun 2005
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised trial of paclitaxel in small cell lung cancer (SCLC) (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoints: Overall Survival up to 5 years, Objective Response Rate up to 5 years and 1 more. Started Apr 1998; status: completed.
02
Drugs
paclitaxel
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00003299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003299.